Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of CDI-45205 for the treatment of patients with COVID-19

Next Previous
Trial Profile

A phase 1 study of CDI-45205 for the treatment of patients with COVID-19

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDI-45205 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

  • 23 Mar 2022 According to a Cocrystal Pharma media release, this trial is expected to initiate in 2022.
  • 27 Jan 2022 According to a Cocrystal Pharma media release, the company has received guidance from the U.S. Food and Drug Administration (FDA) in response to the pre-Investigational New Drug (IND) briefing package earlier this month and FDA's response clarifies the pathway for a planned Phase 1 study and provides direction for a subsequent Phase 2 study.
  • 15 Nov 2021 According to a Cocrystal Pharma media release, the company has sets goal of initiating IND-enabling study and Phase 1 in 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top